Clinical Research Papers:
A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors
Metrics: PDF 684 views | HTML 1747 views | ?
David S. Hong1, Peter Rosen2, A. Craig Lockhart3, Siqing Fu1, Filip Janku1, Razelle Kurzrock1, Rabia Khan1, Benny Amore4, Isaac Caudillo5, Hongjie Deng5, Yuying C. Hwang5, Robert Loberg5, Gataree Ngarmchamnanrith5, Darrin M. Beaupre5 and Peter Lee2
1 MD Anderson Cancer Center, Houston, TX, USA
2 Tower Cancer Research Foundation, Beverly Hills, CA, USA
3 Washington University School of Medicine, St. Louis, MO, USA
4 Amgen Inc., Seattle, WA, USA
5 Amgen Inc., Thousand Oaks, CA, USA
David S. Hong, email:
Keywords: MET, first-in-human, solid tumors, prostate cancer, small molecule
Received: February 04, 2015 Accepted: May 30, 2015 Published: June 19, 2015
Background: This first-in-human study evaluated AMG 208, a small-molecule MET inhibitor, in patients with advanced solid tumors.
Methods: Three to nine patients were enrolled into one of seven AMG 208 dose cohorts (25, 50, 100, 150, 200, 300, and 400 mg). Patients received AMG 208 orally on days 1 and days 4–28 once daily. The primary objectives were to evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of AMG 208.
Results: Fifty-four patients were enrolled. Six dose-limiting toxicities were observed: grade 3 increased aspartate aminotransferase (200 mg), grade 3 thrombocytopenia (200 mg), grade 4 acute myocardial infarction (300 mg), grade 3 prolonged QT (300 mg), and two cases of grade 3 hypertension (400 mg). The MTD was not reached. The most frequent grade ≥3 treatment-related adverse event was anemia (n = 3) followed by hypertension, prolonged QT, and thrombocytopenia (two patients each). AMG 208 exposure increased linearly with dose; mean plasma half-life estimates were 21.4–68.7 hours. One complete response (prostate cancer) and three partial responses (two in prostate cancer, one in kidney cancer) were observed.
Conclusions: In this study, AMG 208 had manageable toxicities and showed evidence of antitumor activity, particularly in prostate cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.